Nurix Therapeutics (NRIX) FCF Margin (2019 - 2025)
Historic FCF Margin for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 537.4%.
- Nurix Therapeutics' FCF Margin fell 1545600.0% to 537.4% in Q4 2025 from the same period last year, while for Nov 2025 it was 313.73%, marking a year-over-year increase of 196600.0%. This contributed to the annual value of 313.73% for FY2025, which is 196600.0% up from last year.
- Latest data reveals that Nurix Therapeutics reported FCF Margin of 537.4% as of Q4 2025, which was down 1545600.0% from 761.29% recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' FCF Margin ranged from a high of 159.01% in Q4 2023 and a low of 761.29% during Q3 2025
- Its 5-year average for FCF Margin is 330.51%, with a median of 351.81% in 2025.
- In the last 5 years, Nurix Therapeutics' FCF Margin plummeted by -12739900bps in 2021 and then surged by 7563800bps in 2023.
- Nurix Therapeutics' FCF Margin (Quarter) stood at 429.6% in 2021, then crashed by -39bps to 597.38% in 2022, then soared by 127bps to 159.01% in 2023, then tumbled by -341bps to 382.84% in 2024, then tumbled by -40bps to 537.4% in 2025.
- Its FCF Margin stands at 537.4% for Q4 2025, versus 761.29% for Q3 2025 and 149.44% for Q2 2025.